Fortress Biotech Yönetim
Yönetim kriter kontrolleri 3/4
Fortress Biotech CEO'su Lindsay Rosenwald, Dec2013 tarihinde atandı, in görev süresi 12.5 yıldır. in toplam yıllık tazminatı $ 2.89M olup, şirket hissesi ve opsiyonları dahil olmak üzere 2.2% maaş ve 97.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 14.1% ine doğrudan sahiptir ve bu hisseler $ 13.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.8 yıl ve 10.9 yıldır.
Anahtar bilgiler
Lindsay Rosenwald
İcra Kurulu Başkanı
US$2.9m
Toplam tazminat
| CEO maaş yüzdesi | 2.17% |
| CEO görev süresi | 12.5yrs |
| CEO sahipliği | 14.1% |
| Yönetim ortalama görev süresi | 7.8yrs |
| Yönetim Kurulu ortalama görev süresi | 10.9yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 05
FBIO: Cash Reserves And Journey Stake Will Drive Future Upside Potential
Analysts have raised their price target on Fortress Biotech stock to $5.00 from $4.50, citing a higher estimated value for the company’s cash position and its Journey Medical stake following the recent Q1 update. What's in the News Analysts raised the Fortress Biotech price target to $5.00 from $4.50, citing an updated assessment of the company’s cash position and its stake in Journey Medical after the recent Q1 update.Seeking Alpha • May 29
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Summary Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO’s recent windfall from the Menkes disease drug sale positions it to easily pay $16 million in deferred FBIOP preferred dividends. FBIOP dividends, deferred for nearly two years, could total $4.69 per share if paid by June 15, 2026, benefiting significant insider holders. FBIO appears undervalued, with cash exceeding the sum of equity market cap, debt, preferred stock at par, and deferred dividends by $24 million. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 12
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.Anlatı Güncellemesi • Apr 25
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.Anlatı Güncellemesi • Apr 11
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.Anlatı Güncellemesi • Mar 27
FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Anlatı Güncellemesi • Mar 12
FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).Anlatı Güncellemesi • Feb 26
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Anlatı Güncellemesi • Feb 11
FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Analiz Makalesi • Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...Anlatı Güncellemesi • Jan 28
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.Anlatı Güncellemesi • Jan 12
FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).Anlatı Güncellemesi • Dec 26
FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earningsAnaliz Makalesi • Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Anlatı Güncellemesi • Dec 12
FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.Analiz Makalesi • Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
Anlatı Güncellemesi • Aug 19
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.Analiz Makalesi • Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...Yeni Anlatı • Jul 06
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Analiz Makalesi • Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Analiz Makalesi • Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...Analiz Makalesi • Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...Analiz Makalesi • Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...Analiz Makalesi • Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$119m |
| Dec 31 2025 | US$3m | US$63k | -US$2m |
| Sep 30 2025 | n/a | n/a | -US$5m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$51m |
| Dec 31 2024 | US$1m | US$63k | -US$56m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$1m | US$63k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$86m |
| Jun 30 2023 | n/a | n/a | -US$104m |
| Mar 31 2023 | n/a | n/a | -US$100m |
| Dec 31 2022 | US$1m | US$63k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$97m |
| Jun 30 2022 | n/a | n/a | -US$93m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$3m | US$60k | -US$65m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$3m | US$59k | -US$47m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$32k | -US$40m |
Tazminat ve Piyasa: Lindsay 'nin toplam tazminatı ($USD 2.89M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.34K ).
Tazminat ve Kazançlar: Lindsay 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Lindsay Rosenwald (71 yo)
12.5yrs
Görev süresi
US$2,887,257
Tazminat
Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 12.5yrs | US$2.89m | 14.1% $ 13.7m | |
| CFO & Head of Corporate Development | 6.1yrs | US$664.08k | 0.065% $ 63.2k | |
| Chief Strategy Officer | 1.2yrs | US$115.00k | 0% $ 0 | |
| Executive Vice Chairman of Strategic Development & Director | 12.3yrs | US$2.44m | 6.85% $ 6.7m | |
| General Counsel & Corporate Secretary | 7.8yrs | Veri yok | Veri yok |
7.8yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş
Deneyimli Yönetim: FBIO 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 16.7yrs | US$2.89m | 14.1% $ 13.7m | |
| Executive Vice Chairman of Strategic Development & Director | 12.5yrs | US$2.44m | 6.85% $ 6.7m | |
| Independent Director | 12.3yrs | US$135.00k | 0.19% $ 185.3k | |
| Scientific Advisor | 9yrs | Veri yok | Veri yok | |
| Independent Director | 10.9yrs | US$200.00k | 0.083% $ 80.4k | |
| Scientific Advisor | 9yrs | Veri yok | Veri yok | |
| Independent Director | 20yrs | US$167.50k | 0.35% $ 339.0k | |
| Scientific Advisor | 9yrs | Veri yok | Veri yok | |
| Scientific Advisor | 9yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 17.5yrs | US$147.50k | 0.010% $ 9.8k | |
| Scientific Advisor | 9yrs | Veri yok | Veri yok |
10.9yrs
Ortalama Görev Süresi
71yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: FBIO 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.9 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/17 17:35 |
| Gün Sonu Hisse Fiyatı | 2026/06/17 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Fortress Biotech, Inc. 13 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |